HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alexandra Koschak Selected Research

congenital stationary Night blindness

1/2021Cav1.4 dysfunction and congenital stationary night blindness type 2.
1/2015Gain-of-function nature of Cav1.4 L-type calcium channels alters firing properties of mouse retinal ganglion cells.
8/2014Spectrum of Cav1.4 dysfunction in congenital stationary night blindness type 2.
7/2013What can naturally occurring mutations tell us about Ca(v)1.x channel function?
9/2006C-terminal modulator controls Ca2+-dependent gating of Ca(v)1.4 L-type Ca2+ channels.
3/2006Effects of congenital stationary night blindness type 2 mutations R508Q and L1364H on Cav1.4 L-type Ca2+ channel function and expression.
1/2005Congenital stationary night blindness type 2 mutations S229P, G369D, L1068P, and W1440X alter channel gating or functional expression of Ca(v)1.4 L-type Ca2+ channels.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alexandra Koschak Research Topics

Disease

7congenital stationary Night blindness
01/2021 - 01/2005
3Channelopathies
01/2018 - 10/2004
2Deafness (Deaf Mutism)
07/2013 - 01/2011
1Retinitis Pigmentosa (Pigmentary Retinopathy)
01/2021
1Blindness (Hysterical Blindness)
01/2021
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2020
1Chronic Pain
10/2015
1Absence Epilepsy (Childhood Absence Epilepsy)
10/2015
1Hypertension (High Blood Pressure)
10/2015
1Pain (Aches)
10/2015
1Intractable Pain
10/2015
1Brugada Syndrome
07/2013
1Jervell-Lange Nielsen Syndrome (Jervell and Lange-Nielsen Syndrome)
01/2011
1Cardiac Arrhythmias (Arrythmia)
01/2011
1Migraine Disorders (Migraine)
07/2009
1Central Nervous System Diseases (CNS Diseases)
02/2009
1Ataxia (Dyssynergia)
03/2002
1Type 2 Episodic Ataxia
03/2002

Drug/Important Bio-Agent (IBA)

9Retinaldehyde (Retinal)IBA
01/2021 - 01/2005
4voltage-dependent calcium channel (P-Q type)IBA
07/2010 - 03/2002
3L-Type Calcium Channels (Dihydropyridine Receptor)IBA
01/2021 - 01/2005
3Protein Isoforms (Isoforms)IBA
10/2015 - 10/2004
2Proteins (Proteins, Gene)FDA Link
01/2021 - 01/2018
2Pharmaceutical PreparationsIBA
10/2015 - 02/2009
1Biomarkers (Surrogate Marker)IBA
01/2020
1Ion Channels (Ion Channel)IBA
01/2018
1Ethosuximide (Zarontin)FDA LinkGeneric
10/2015
1Peptides (Polypeptides)IBA
10/2015
1Calcium Channels (Calcium Channel)IBA
10/2015
1N-Type Calcium Channels (N-Type Calcium Channel)IBA
10/2015
1Therapeutic UsesIBA
10/2015
1ziconotide (Prialt)FDA Link
10/2015
1Delayed Rectifier Potassium ChannelsIBA
01/2011